About Ryanodine receptor 3
Ryanodine receptor 3 (RYR3) is a protein
from Homo sapiens identified by UniProt accession
Q15413, 4870 residues long.
MolForge cross-references it against 0 known binders and
162 disease associations.
Target properties
| Protein name | Ryanodine receptor 3 |
|---|
| UniProt accession | Q15413 |
|---|
| Gene | RYR3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 4870 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (162)
Diseases linked to this target (Open Targets).
- Fever · score 0.53
- multiple sclerosis · score 0.47
- Spinal cord injury · score 0.46
- cerebral palsy · score 0.46
- Spasticity · score 0.46
- stroke · score 0.46
- neurodegenerative disease · score 0.37
- nemaline myopathy · score 0.37
- hydrops fetalis · score 0.34
- vesiculobullous skin disease · score 0.33
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (4870 residues)
MAEGGEGGED EIQFLRTEDE VVLQCIATIH KEQRKFCLAA EGLGNRLCFL EPTSEAKYIP PDLCVCNFVL EQSLSVRALQ EMLANTGENG GEGAAQGGGH RTLLYGHAVL LRHSFSGMYL TCLTTSRSQT DKLAFDVGLR EHATGEACWW TIHPASKQRS EGEKVRIGDD LILVSVSSER YLHLSVSNGN IQVDASFMQT LWNVHPTCSG SSIEEGYLLG GHVVRLFHGH DECLTIPSTD QNDSQHRRIF YEAGGAGTRA RSLWRVEPLR ISWSGSNIRW GQAFRLRHLT TGHYLALTED QGLILQDRAK SDTKSTAFSF RASKELKEKL DSSHKRDIEG MGVPEIKYGD SVCFVQHIAS GLWVTYKAQD AKTSRLGPLK RKVILHQEGH MDDGLTLQRC QREESQAARI IRNTTALFSQ FVSGNNRTAA PITLPIEEVL QTLQDLIAYF QPPEEEMRHE DKQNKLRSLK NRQNLFKEEG MLALVLNCID RLNVYNSVAH FAGIAREESG MAWKEILNLL YKLLAALIRG NRNNCAQFSN NLDWLISKLD RLESSSGILE VLHCILTESP EALNLIAEGH IKSIISLLDK HGRNHKVLDI LCSLCLCNGV AVRANQNLIC DNLLPRRNLL LQTRLINDVT SIRPNIFLGV AEGSAQYKKW YFELIIDQVD PFLTAEPTHL RVGWASSSGY APYPGGGEGW GGNGVGDDLY SYGFDGLHLW SGRIPRAVAS INQHLLRSDD VVSCCLDLGV PSISFRINGQ PVQGMFENFN TDGLFFPVMS FSAGVKVRFL MGGRHGEFKF LPPSGYAPCY EALLPKEKMR LEPVKEYKRD ADGIRDLLGT TQFLSQASFI PCPVDTSQVI LPPHLEKIRD RLAENIHELW GMNKIELGWT FGKIRDDNKR QHPCLVEFSK LPETEKNYNL QMSTETLKTL LALGCHIAHV NPAAEEDLKK VKLPKNYMMS NGYKPAPLDL SDVKLLPPQE ILVDKLAENA HNVWAKDRIK QGWTYGIQQD LKNKRNPRLV PYALLDERTK KSNRDSLREA VRTFVGYGYN IEPSDQELAD SAVEKVSIDK IRFFRVERSY AVRSGKWYFE FEVVTGGDMR VGWARPGCRP DVELGADDQA FVFEGNRGQR WHQGSGYFGR TWQPGDVVGC MINLDDASMI FTLNGELLIT NKGSELAFAD YEIENGFVPI CCLGLSQIGR MNLGTDASTF KFYTMCGLQE GFEPFAVNMN RDVAMWFSKR LPTFVNVPKD HPHIEVMRID GTMDSPPCLK VTHKTFGTQN SNADMIYCRL SMPVECHSSF SHSPCLDSEA FQKRKQMQEI LSHTTTQCYY AIRIFAGQDP SCVWVGWVTP DYHLYSEKFD LNKNCTVTVT LGDERGRVHE SVKRSNCYMV WGGDIVASSQ RSNRSNVDLE IGCLVDLAMG MLSFSANGKE LGTCYQVEPN TKVFPAVFLQ PTSTSLFQFE LGKLKNAMPL SAAIFRSEEK NPVPQCPPRL DVQTIQPVLW SRMPNSFLKV ETERVSERHG WVVQCLEPLQ MMALHIPEEN RCVDILELCE QEDLMRFHYH TLRLYSAVCA LGNSRVAYAL CSHVDLSQLF YAIDNKYLPG LLRSGFYDLL ISIHLASAKE RKLMMKNEYI IPITSTTRNI RLFPDESKRH GLPGVGLRTC LKPGFRFSTP CFVVTGEDHQ KQSPEIPLES LRTKALSMLT EAVQCSGAHI RDPVGGSVEF QFVPVLKLIG TLLVMGVFDD DDVRQILLLI DPSVFGEHSA GTEEGAEKEE VTQVEEKAVE AGEKAGKEAP VKGLLQTRLP ESVKLQMCEL LSYLCDCELQ HRVEAIVAFG DIYVSKLQAN QKFRYNELMQ ALNMSAALTA RKTKEFRSPP QEQINMLLNF QLGENCPCPE EIREELYDFH EDLLLHCGVP LEEEEEEEED TSWTGKLCAL VYKIKGPPKP EKEQPTEEEE RCPTTLKELI SQTMICWAQE DQIQDSELVR MMFNLLRRQY DSIGELLQAL RKTYTISHTS VSDTINLLAA LGQIRSLLSV RMGKEEELLM INGLGDIMNN KVFYQHPNLM RVLGMHETVM EVMVNVLGTE KSQIAFPKMV ASCCRFLCYF CRISRQNQKA MFEHLSYLLE NSSVGLASPS MRGSTPLDVA ASSVMDNNEL ALSLEEPDLE KVVTYLAGCG LQSCPMLLAK GYPDVGWNPI EGERYLSFLR FAVFVNSESV EENASVVVKL LIRRPECFGP ALRGEGGNGL LAAMQGAIKI SENPALDLPS QGYKREVSTG DDEEEEEIVH MGNAIMSFYS ALIDLLGRCA PEMHLIQTGK GEAIRIRSIL RSLVPTEDLV GIISIPLKLP SLNKDGSVSE PDMAANFCPD HKAPMVLFLD RVYGIKDQTF LLHLLEVGFL PDLRASASLD TVSLSTTEAA LALNRYICSA VLPLLTRCAP LFAGTEHCTS LIDSTLQTIY RLSKGRSLTK AQRDTIEECL LAICNHLRPS MLQQLLRRLV FDVPQLNEYC KMPLKLLTNH YEQCWKYYCL PSGWGSYGLA VEEELHLTEK LFWGIFDSLS HKKYDPDLFR MALPCLSAIA GALPPDYLDT RITATLEKQI SVDADGNFDP KPINTMNFSL PEKLEYIVTK YAEHSHDKWA CDKSQSGWKY GISLDENVKT HPLIRPFKTL TEKEKEIYRW PARESLKTML AVGWTVERTK EGEALVQQRE NEKLRSVSQA NQGNSYSPAP LDLSNVVLSR ELQGMVEVVA ENYHNIWAKK KKLELESKGG GSHPLLVPYD TLTAKEKFKD REKAQDLFKF LQVNGIIVSR GMKDMELDAS SMEKRFAYKF LKKILKYVDS AQEFIAHLEA IVSSGKTEKS PRDQEIKFFA KVLLPLVDQY FTSHCLYFLS SPLKPLSSSG YASHKEKEMV AGLFCKLAAL VRHRISLFGS DSTTMVSCLH ILAQTLDTRT VMKSGSELVK AGLRAFFENA AEDLEKTSEN LKLGKFTHSR TQIKGVSQNI NYTTVALLPI LTSIFEHVTQ HQFGMDLLLG DVQISCYHIL CSLYSLGTGK NIYVERQRPA LGECLASLAA AIPVAFLEPT LNRYNPLSVF NTKTPRERSI LGMPDTVEDM CPDIPQLEGL MKEINDLAES GARYTEMPHV IEVILPMLCN YLSYWWERGP ENLPPSTGPC CTKVTSEHLS LILGNILKII NNNLGIDEAS WMKRIAVYAQ PIISKARPDL LRSHFIPTLE KLKKKAVKTV QEEEQLKADG KGDTQEAELL ILDEFAVLCR DLYAFYPMLI RYVDNNRSNW LKSPDADSDQ LFRMVAEVFI LWCKSHNFKR EEQNFVIQNE INNLAFLTGD SKSKMSKAMQ VKSGGQDQER KKTKRRGDLY SIQTSLIVAA LKKMLPIGLN MCTPGDQELI SLAKSRYSHR DTDEEVREHL RNNLHLQEKS DDPAVKWQLN LYKDVLKSEE PFNPEKTVER VQRISAAVFH LEQVEQPLRS KKAVWHKLLS KQRKRAVVAC FRMAPLYNLP RHRSINLFLH GYQRFWIETE EYSFEEKLVQ DLAKSPKVEE EEEEETEKQP DPLHQIILYF SRNALTERSK LEDDPLYTSY SSMMAKSCQS GEDEEEDEDK EKTFEEKEME KQKTLYQQAR LHERGAAEMV LQMISASKGE MSPMVVETLK LGIAILNGGN AGVQQKMLDY LKEKKDAGFF QSLSGLMQSC SVLDLNAFER QNKAEGLGMV TEEGTLIVRE RGEKVLQNDE FTRDLFRFLQ LLCEGHNSDF QNFLRTQMGN TTTVNVIIST VDYLLRLQES ISDFYWYYSG KDIIDESGQH NFSKALAVTK QIFNSLTEYI QGPCIGNQQS LAHSRLWDAV VGFLHVFANM QMKLSQDSSQ IELLKELLDL LQDMVVMLLS LLEGNVVNGT IGKQMVDTLV ESSTNVEMIL KFFDMFLKLK DLTSSDTFKE YDPDGKGIIS KKEFQKAMEG QKQYTQSEID FLLSCAEADE NDMFNYVDFV DRFHEPAKDI GFNVAVLLTN LSEHMPNDSR LKCLLDPAES VLNYFEPYLG RIEIMGGAKK IERVYFEISE SSRTQWEKPQ VKESKRQFIF DVVNEGGEQE KMELFVNFCE DTIFEMQLAS QISESDSADR PEEEEEDEDS SYVLEIAGEE EEDGSLEPAS AFAMACASVK RNVTDFLKRA TLKNLRKQYR NVKKMTAKEL VKVLFSFFWM LFVGLFQLLF TILGGIFQIL WSTVFGGGLV EGAKNIRVTK ILGDMPDPTQ FGIHDDTMEA ERAEVMEPGI TTELVHFIKG EKGDTDIMSD LFGLHPKKEG SLKHGPEVGL GDLSEIIGKD EPPTLESTVQ KKRKAQAAEM KAANEAEGKV ESEKADMEDG EKEDKDKEEE QAEYLWTEVT KKKKRRCGQK VEKPEAFTAN FFKGLEIYQT KLLHYLARNF YNLRFLALFV AFAINFILLF YKVTEEPLEE ETEDVANLWN SFNDEEEEEA MVFFVLQEST GYMAPTLRAL AIIHTIISLV CVVGYYCLKV PLVVFKREKE IARKLEFDGL YITEQPSEDD IKGQWDRLVI NTPSFPNNYW DKFVKRKVIN KYGDLYGAER IAELLGLDKN ALDFSPVEET KAEAASLVSW LSSIDMKYHI WKLGVVFTDN SFLYLAWYTT MSVLGHYNNF FFAAHLLDIA MGFKTLRTIL SSVTHNGKQL VLTVGLLAVV VYLYTVVAFN FFRKFYNKSE DDDEPDMKCD DMMTCYLFHM YVGVRAGGGI GDEIEDPAGD PYEMYRIVFD ITFFFFVIVI LLAIIQGLII DAFGELRDQQ EQVREDMETK CFICGIGNDY FDTTPHGFET HTLQEHNLAN YLFFLMYLIN KDETEHTGQE SYVWKMYQER CWDFFPAGDC FRKQYEDQLG
Explore Ryanodine receptor 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets